logo

Day One Biopharmaceuticals, Inc. (DAWN)



Trade DAWN now with
  Date
  Headline
5/16/2022 11:09:17 AM Wedbush Is Lowering Day One Biopharmaceuticals, Inc. (DAWN) FY22 Estimate To -2.06 From -1.46
5/16/2022 11:09:05 AM Wedbush Is Lowering Day One Biopharmaceuticals, Inc. (DAWN) Q4 22 Estimate To -0.56 From -0.40
5/16/2022 11:08:47 AM Wedbush Is Cutting Day One Biopharmaceuticals, Inc. (DAWN) Q3 22 Estimate To -0.53 From -0.37
5/16/2022 11:08:34 AM Wedbush Is Cutting Day One Biopharmaceuticals, Inc. (DAWN) Q2 22 Estimate To -0.50 From -0.35
5/16/2022 11:05:55 AM Wedbush Reiterates Day One Biopharmaceuticals, Inc. (DAWN) At Outperform With $32 Price Target
3/8/2022 8:10:15 AM Wedbush Is Cutting Day One Biopharmaceuticals, Inc. (DAWN) FY22 Estimate To -1.46 From -1.41
3/8/2022 8:09:56 AM Wedbush Is Lowering Day One Biopharmaceuticals, Inc. (DAWN) Q4 22 Estimate To -0.40 From -0.38
3/8/2022 8:09:31 AM Wedbush Is Lowering Day One Biopharmaceuticals, Inc. (DAWN) Q3 22 Estimate To -0.37 From -0.36
3/8/2022 8:09:15 AM Wedbush Is Cutting Day One Biopharmaceuticals, Inc. (DAWN) Q2 22 Estimate To -0.35 From -0.34
3/8/2022 8:08:48 AM Wedbush Is Lowering Day One Biopharmaceuticals, Inc. (DAWN) Q1 22 Estimate To -0.33 From -0.32
3/8/2022 8:08:17 AM Wedbush Reiterates Day One Biopharmaceuticals, Inc. (DAWN) At Outperform With $32 Price Target
11/22/2021 7:11:35 AM Day One Doses First Patient In Phase 2 Monotherapy Study In RAF-altered Solid Tumors
7/27/2021 8:54:27 AM Day One Receives FDA Rare Pediatric Disease Designation For DAY101 For Pediatric Low-Grade Glioma